TY - JOUR
T1 - TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation
AU - Wang, Jing
AU - Peng, Yan
AU - Sun, Hongxia
AU - Aung, Phyu P.
AU - Resetkova, Erika
AU - Yam, Clinton
AU - Sahin, Aysegul A.
AU - Huo, Lei
AU - Ding, Qingqing
N1 - Publisher Copyright:
© 2024 College of American Pathologists. All rights reserved.
PY - 2024/2
Y1 - 2024/2
N2 - Context.—The recently identified immunohistochemical marker TRPS1 is highly sensitive and specific for invasive breast carcinoma, especially triple-negative breast carcinoma. However, TRPS1 expression in special morphologic subtypes of breast cancer is unclear. Objective.—To investigate the expression of TRPS1 in invasive breast cancer with apocrine differentiation, in comparison to the expression of GATA3. Design.—A total of 52 invasive breast carcinomas with apocrine differentiation, comprising 41 triple-negative breast carcinomas and 11 estrogen receptor (ER) and progesterone receptor (PR)–negative, human epidermal growth factor receptor 2 (HER2)–positive cases, along with 11 triple-negative breast carcinomas without apocrine differentiation, were evaluated for TRPS1 and GATA3 expression by immunohistochemistry. All tumors were diffusely positive (.90%) for androgen receptor (AR). Results.—Triple-negative breast carcinoma with apocrine differentiation had positive TRPS1 expression in 12% of cases (5 of 41), whereas GATA3 was positive in all cases. Similarly, HER2+/ER– invasive breast carcinoma with apocrine differentiation showed positive TRPS1 in 18% of cases (2 of 11), whereas GATA3 was positive in all cases. In contrast, triple-negative breast carcinoma with strong AR expression but without apocrine differentiation showed both TRPS1 and GATA3 expression in 100% (11 of 11) of cases. Conclusions.—Most ER–/PR–/AR+ invasive breast carcinomas with apocrine differentiation are TRPS1 negative and GATA3 positive, regardless of HER2 status. Therefore, TRPS1 negativity does not exclude breast origin in tumors with apocrine differentiation. A panel of TRPS1 and GATA3 immunostains can be helpful when the tissue origin of such tumors is clinically relevant.
AB - Context.—The recently identified immunohistochemical marker TRPS1 is highly sensitive and specific for invasive breast carcinoma, especially triple-negative breast carcinoma. However, TRPS1 expression in special morphologic subtypes of breast cancer is unclear. Objective.—To investigate the expression of TRPS1 in invasive breast cancer with apocrine differentiation, in comparison to the expression of GATA3. Design.—A total of 52 invasive breast carcinomas with apocrine differentiation, comprising 41 triple-negative breast carcinomas and 11 estrogen receptor (ER) and progesterone receptor (PR)–negative, human epidermal growth factor receptor 2 (HER2)–positive cases, along with 11 triple-negative breast carcinomas without apocrine differentiation, were evaluated for TRPS1 and GATA3 expression by immunohistochemistry. All tumors were diffusely positive (.90%) for androgen receptor (AR). Results.—Triple-negative breast carcinoma with apocrine differentiation had positive TRPS1 expression in 12% of cases (5 of 41), whereas GATA3 was positive in all cases. Similarly, HER2+/ER– invasive breast carcinoma with apocrine differentiation showed positive TRPS1 in 18% of cases (2 of 11), whereas GATA3 was positive in all cases. In contrast, triple-negative breast carcinoma with strong AR expression but without apocrine differentiation showed both TRPS1 and GATA3 expression in 100% (11 of 11) of cases. Conclusions.—Most ER–/PR–/AR+ invasive breast carcinomas with apocrine differentiation are TRPS1 negative and GATA3 positive, regardless of HER2 status. Therefore, TRPS1 negativity does not exclude breast origin in tumors with apocrine differentiation. A panel of TRPS1 and GATA3 immunostains can be helpful when the tissue origin of such tumors is clinically relevant.
UR - http://www.scopus.com/inward/record.url?scp=85175348436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175348436&partnerID=8YFLogxK
U2 - 10.5858/arpa.2022-0289-OA
DO - 10.5858/arpa.2022-0289-OA
M3 - Article
C2 - 37074839
AN - SCOPUS:85175348436
SN - 0003-9985
VL - 148
SP - 200
EP - 205
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 2
ER -